

S1 Table. EORTC scores at baseline

Dimension	CCRT with TMZ +TMZ 6cycles (n=40)	RT only (n=44)	p-value ^{a)}
EORTC QLQ-C30			
Global health status/QoL			
Global health status/QoL	50.0 (0.0-100.0)	66.7 (16.7-100.0)	0.342
Functional scales			
Physical functioning	80.0 (20.0-100.0)	80.0 (20.0-100.0)	0.960
Role functioning	83.3 (0.0-100.0)	83.3 (16.7-100.0)	0.643
Emotional functioning	75.0 (25.0-100.0)	75.0 (41.7-100.0)	0.493
Cognitive functioning	83.3 (0.0-100.0)	83.3 (33.3-100.0)	0.654
Social functioning	66.7 (0.0-100.0)	83.3 (0.0-100.0)	0.264
Symptom scales			
Fatigue	22.2 (0.0-88.9)	22.2 (0.0-66.7)	0.572
Nausea and vomiting	0.0 (0.0-66.7)	0.0 (0.0-66.7)	0.770
Pain	16.7 (0.0-83.3)	16.7 (0.0-66.7)	0.742
Dyspnea	0.0 (0.0-66.7)	0.0 (0.0-66.7)	0.674
Insomnia	16.7 (0.0-66.7)	0.0 (0.0-100.0)	0.988
Appetite loss	0.0 (0.0-100.0)	0.0 (0.0-100.0)	0.947
Constipation	0.0 (0.0-100.0)	0.0 (0.0-100.0)	0.945
Diarrhea	0.0 (0.0-66.7)	0.0 (0.0-66.7)	0.814
Financial difficulties	16.7 (0.0-100.0)	33.3 (0.0-100.0)	0.784
EORTC QLQ-BN20			
Future uncertainty	25.0 (0.0-91.7)	25.0 (0.0-91.7)	0.204
Visual disorder	0.0 (0.0-100.0)	11.1 (0.0-66.7)	0.616
Motor dysfunction	22.2 (0.0-100.0)	11.1 (0.0-66.7)	0.067
Communication deficit	11.1 (0.0-88.9)	0.0 (0.0-88.9)	0.408
Headaches	33.3 (0.0-100.0)	0.0 (0.0-66.7)	0.733
Seizures	0.0 (0.0-66.7)	0.0 (0.0-33.3)	0.142
Drowsiness	33.3 (0.0-100.0)	33.3 (0.0-100.0)	0.139
Itchy skin	0.0 (0.0-66.7)	0.0 (0.0-66.7)	0.452
Hair loss	0.0 (0.0-66.7)	0.0 (0.0-66.7)	0.479
Weakness of legs	33.3 (0.0-100.0)	33.3 (0.0-66.7)	0.992
Bladder control	0.0 (0.0-66.7)	0.0 (0.0-66.7)	0.723

Values are presented as median (min-max). CCRT, concurrent chemoradiotherapy; EORTC, European Organization for Research and Treatment of Cancer; QLQ-BN20, 20-item EORTC QLQ-Brain Neoplasm; QLQ-C30, Quality of Life Questionnaire 30; QoL, quality of life; RT, radiotherapy; TMZ, temozolomide. ^{a)}Wilcoxon rank sum test.